Evidence map›Paper›PMID 35024177›Full record

ArticleJournal of advanced research2021

Oxyphylla A ameliorates cognitive deficits and alleviates neuropathology via the Akt-GSK3β and Nrf2-Keap1-HO-1 pathways in

Yaqi Bian, Yan Chen, Xiufen Wang, Guozhen Cui, Carolina Oi Lam Ung, Jia-Hong Lu, Weihong Cong, Benqin Tang, Simon Ming-Yuen Lee

Open access · goldAbstract read
In one paragraph

Article in Journal of advanced research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Neuroprotective Effects and Mechanisms ofInternational journal of molecular sciences · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Effects ofFrontiers in veterinary science · 2025
    Article
  19. Article
  20. Toxicological evaluation ofToxicology reports · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Yaqi BianState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Yan ChenState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Xiufen WangState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Guozhen CuiDepartment of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, China.
Carolina Oi Lam UngState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Jia-Hong LuState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Weihong CongLaboratory of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Benqin TangDepartment of Medical Science, Shunde Polytechnic, Foshan, China.
Simon Ming-Yuen LeeState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
University of Macau · MOShunde Polytechnic · CNXiyuan Hospital · CNZunyi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Alzheimer's disease (AD) is a progressive brain disorder, and one of the most common causes of dementia and amnesia. Due to the complex pathogenesis of AD, the underlying mechanisms remain unclear. Although scientists have made increasing efforts to develop drugs for AD, no effective therapeutic agents have been found. Objectives: Natural products and their constituents have shown promise for treating neurodegenerative diseases, including AD. Thus, in-depth study of medical plants, and the main active ingredients thereof against AD, is necessary to devise therapeutic agents. Methods: In this study, N2a/APP cells and SAMP8 mice were employed as Results: Results showed that oxyphylla A, a novel compound extracted from Alpinia oxyphylla, could reduce the expression levels of amyloid precursor protein (APP) and amyloid beta (Aβ) proteins, and attenuate cognitive decline in SAMP8 mice. Further investigation of the underlying mechanisms showed that oxyphylla A exerted an antioxidative effect through the Akt-GSK3β and Nrf2-Keap1-HO-1 pathways.Conclusions.Taken together, our results suggest a new horizon for the discovery of therapeutic agents for AD.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesAnimalsCaproatesCognitionCresolsDisease Models, AnimalGlycogen Synthase Kinase 3 betaKelch-Like ECH-Associated Protein 1MiceNF-E2-Related Factor 2Oxidative StressProto-Oncogene Proteins c-aktAmyloid beta-PeptidesCaproatesCresolsGlycogen Synthase Kinase 3 betaKeap1 protein, mouseKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2oxyphylla AProto-Oncogene Proteins c-aktAD, Alzheimer’s diseaseAlzheimer’s diseaseAmyloid beta proteinsAOE, ethanolic extract of Alpinia oxyphyllaAPP, amyloid precursor proteinARE, antioxidant response elementARE, antioxidant responsive elementAβ, amyloid betaGSK3, glycogen synthase kinase 3HO-1, heme oxygenase-1Keap1, Keleh-like ECH-associated proteinMWM, Morris Water MazeNFTs, neurofibrillary tanglesNQO1, NAD(P)H:quinone oxidoreductase1Nrf2, erythroid-derived 2-related factor 2Oxidative stressoxyphylla APD, Parkinson’s diseasePHF, paired helical filamentspRL-TK, Renilla luciferase reporter plasmidRLU, relative luciferase unitsROS, reactive oxygen speciesSAMP8SAMP8 mice, senescence-accelerated mouse prone 8

Identifiers

PMID35024177
PMCPMC8655137
OpenAlexW3198631777

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.